new glp 1 agonist for weight loss GLP-1 Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Drugs for Weight Loss:
Description
Roseberry, I
Clinical trials of GLP-1RAs have primarily focused on patients with obesity or overweight, yet the effectiveness in the cardiovascular protection appears independent of baseline BMI range (265)
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
In December 2024, a phase IIa dose-ranging trial (NCT06717425 ) to investigate this drug began, and is due to end in December 2025 5
It acts on two hormone receptors: GLP and glucose-dependent insulinotropic polypeptide (GIP)
Cell Metab 34, 16541674 (2022)
This has led to patients seeking access to these medications through online companies or compounding pharmacies
